Motolimod

Motolimod (VTX-2337) is a drug which acts as a potent and selective agonist of toll-like receptor 8 (TLR8), a receptor involved in the regulation of the immune system. It is used to stimulate the immune system, and has potential application as an adjuvant therapy in cancer chemotherapy, although clinical trials have shown only modest benefits.^[1][2] It also worsens neuropathic pain in animal models and has been used to research the potential of targeting TLR8 in some kinds of chronic pain syndromes.^[3][4]

Motolimod

Identifiers
IUPAC name 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
CAS Number	926927-61-9
PubChem CID	16049404
DrugBank	DB12303
ChemSpider	13177800
UNII	WP6PY72ZH3
KEGG	D10716
ChEMBL	ChEMBL3301618
CompTox Dashboard (EPA)	DTXSID10239107
Chemical and physical data
Formula	C28H34N4O2
Molar mass	458.606 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
InChI InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30) Key:QSPOQCXMGPDIHI-UHFFFAOYSA-N

See also

• Imiquimod
• Vesatolimod